Skip to content

Cadence Research & Consulting

Services
Insight
About
Contact

Consulting Case Studies

View Scientific Content – White Papers >>

Follow Us

Facebook
LinkedIn

Terms of Use
Privacy Policy
About
Contact
Blog

Recent Posts

Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer
Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma
Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC
Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer